Clinical Impact of COVID-19 by P.1 SARS-CoV-2 Lineage
Clinical Impact of Coronavirus Disease 19 (COVID-19) Caused by P.1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lineage
Since the first report of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) P.1 in Manaus, Brazil, a rapid spread of this lineage across the country has been observed. Recent studies indicate that this variant is associated with higher transmissibility; it is not known whether it is associated with clinical severity and higher mortality rates.
This is a retrospective cohort study carried out at Hospital de Clínicas de Porto Alegre. Adult patients aged 18 years or more and 65 years or less who were admitted to the hospital due to symptomatic COVID-19 from June 2020 to May 2021 and had a reverse transcriptase-polymerase chain reaction (RT-PCR) cycle threshold value for either SARS-CoV-2 N1 or N2 target ≤ 25 were eligible to the study. Samples from 86 patients (43 from June 2020 to November 2020 and 43 from February 2021 to May 2021) were sequenced for further evaluation. These dates were defined since the emergence of P.1 lineage in late January.
Clinical data regarding ventilatory support, date of onset of symptoms, laboratory findings and mortality were collected from each patient. This retrospective cohort aims to assess whether the number of days needed for supplementary oxygen either by noninvasive ventilation or high-flow nasal cannula from onset of symptoms differs among patients infected with the P.1 SARS-CoV-2 variant and those infected with other variants.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
RS
-
Porto Alegre, RS, Brasil, 90035-903
- Hospital de Clinicas de Porto Alegre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Patients aged 18 to 65 years
- Hospital admission due to symptomatic COVID-19
- RT-PCR was collected from June to November 2020 or from February to May 2021
Exclusion Criteria:
- Patients admitted for reasons other than COVID-19
- Asymptomatic patients with positive routine screening with RT-PCR
- Patients transferred from other institutions
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
P.1
Patients infected with the P.1 SARS-CoV-2 variant
|
Collection of clinical and laboratory data
|
|
Other variants
Patients infected with SARS-CoV-2 variants other than P.1
|
Collection of clinical and laboratory data
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to Advanced Respiratory Support
Prazo: 28 days from onset of symptoms
|
Number of days needed for supplementary oxygen either by noninvasive ventilation or high-flow nasal cannula from onset of symptoms.
|
28 days from onset of symptoms
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of patients in each category in the ordinal scale during hospitalization
Prazo: 28 days from hospital admission
|
Proportion of patients in each category in the ordinal scale during hospitalization.
Ordinal scale levels: 1, patient not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation or extracorporeal membrane oxygenation; and 6, death.
|
28 days from hospital admission
|
|
Arterial oxygen partial pressure (PaO2)/ Fractional inspired oxygen (FiO2) evolution during hospitalization
Prazo: 28 day from hospital admission
|
Proportion of patients in each category according to PaO2/FiO2 value: 400-301, 300-201, 200-101, <=100.
|
28 day from hospital admission
|
|
28-day Mortality from onset of symptoms
Prazo: 28 days from onset of symptoms
|
Death for any cause from onset of symptoms
|
28 days from onset of symptoms
|
|
Time to death from onset of symptoms
Prazo: 28 days from onset of symptoms
|
Number of days from the onset of symptoms to death
|
28 days from onset of symptoms
|
|
28-day Mortality from hospital admission
Prazo: 28 days from hospital admission
|
Death for any cause from hospital admission
|
28 days from hospital admission
|
|
Time to death from hospital admission
Prazo: 28 days from hospital admission
|
Number of days from the hospital admission to death
|
28 days from hospital admission
|
|
Days alive and free of supplemental oxygen support.
Prazo: 28 day from hospital admission
|
Number of days alive and free of supplemental oxygen support
|
28 day from hospital admission
|
|
Time to invasive ventilatory support
Prazo: 28 days from onset of symptoms
|
Number of days from the onset of symptoms to mechanical ventilation or Extracorporeal membrane oxygenation (ECMO)
|
28 days from onset of symptoms
|
|
Need of critical care
Prazo: 28 days from hospital admission
|
Proportion of patients admitted to Intensive Care Unit
|
28 days from hospital admission
|
|
In-hospital mortality
Prazo: 90 days from hospital admission
|
Death for any cause during hospitalization
|
90 days from hospital admission
|
|
Number of thromboembolic event
Prazo: 28 day from hospital admission
|
Number of patients with documented deep venous thrombosis or pulmonary embolism
|
28 day from hospital admission
|
|
Number of patients requiring renal replacement therapy (RRT)
Prazo: 28 day from hospital admission
|
Number of patients requiring any form of RRT during hospitalization
|
28 day from hospital admission
|
|
Number of patients requiring prone positioning
Prazo: 28 day from hospital admission
|
Number of patients requiring prone positioning during hospitalization
|
28 day from hospital admission
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2020-0163
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Dados/documentos do estudo
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .